392 related articles for article (PubMed ID: 27177084)
21. Hypoxia potentiates gemcitabine-induced stemness in pancreatic cancer cells through AKT/Notch1 signaling.
Zhang Z; Han H; Rong Y; Zhu K; Zhu Z; Tang Z; Xiong C; Tao J
J Exp Clin Cancer Res; 2018 Nov; 37(1):291. PubMed ID: 30486896
[TBL] [Abstract][Full Text] [Related]
22. Oncogenic TRIM31 confers gemcitabine resistance in pancreatic cancer via activating the NF-κB signaling pathway.
Yu C; Chen S; Guo Y; Sun C
Theranostics; 2018; 8(12):3224-3236. PubMed ID: 29930725
[No Abstract] [Full Text] [Related]
23. Ratio of phosphorylated HSP27 to nonphosphorylated HSP27 biphasically acts as a determinant of cellular fate in gemcitabine-resistant pancreatic cancer cells.
Kang D; Choi HJ; Kang S; Kim SY; Hwang YS; Je S; Han Z; Kim JH; Song JJ
Cell Signal; 2015 Apr; 27(4):807-17. PubMed ID: 25615626
[TBL] [Abstract][Full Text] [Related]
24. ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells.
Liu M; Zhang Y; Yang J; Cui X; Zhou Z; Zhan H; Ding K; Tian X; Yang Z; Fung KA; Edil BH; Postier RG; Bronze MS; Fernandez-Zapico ME; Stemmler MP; Brabletz T; Li YP; Houchen CW; Li M
Gastroenterology; 2020 Feb; 158(3):679-692.e1. PubMed ID: 31711924
[TBL] [Abstract][Full Text] [Related]
25. Shikonin suppresses tumor growth and synergizes with gemcitabine in a pancreatic cancer xenograft model: Involvement of NF-κB signaling pathway.
Wang Y; Zhou Y; Jia G; Han B; Liu J; Teng Y; Lv J; Song Z; Li Y; Ji L; Pan S; Jiang H; Sun B
Biochem Pharmacol; 2014 Apr; 88(3):322-33. PubMed ID: 24522113
[TBL] [Abstract][Full Text] [Related]
26. Synergy of gemcitabine and lidamycin associated with NF-kappaB downregulation in pancreatic carcinoma cells.
Chen J; Wu SY; Ou-Yang ZG; Zhen YS
Acta Pharmacol Sin; 2008 May; 29(5):614-9. PubMed ID: 18430374
[TBL] [Abstract][Full Text] [Related]
27. [Role of nuclear factor-kappaB on emodin-induced sensitization of pancreatic cancer to gemcitabine].
Liu A; Hu YS; Wang ZH; Tang LL; Ke PY; Lin SZ
Yao Xue Xue Bao; 2011 Feb; 46(2):146-52. PubMed ID: 21542284
[TBL] [Abstract][Full Text] [Related]
28. Silencing pancreatic adenocarcinoma upregulated factor (PAUF) increases the sensitivity of pancreatic cancer cells to gemcitabine.
Gao CC; Xu XL; Li F; Gong BG; Liu S; Cui YQ; Sun HC; Xu PY; Zheng YM; Jiang H
Tumour Biol; 2016 Jun; 37(6):7555-64. PubMed ID: 26684804
[TBL] [Abstract][Full Text] [Related]
29. Coix seed emulsion synergistically enhances the antitumor activity of gemcitabine in pancreatic cancer through abrogation of NF-κB signaling.
Qian Y; Yang B; Xiong Y; Gu M
Oncol Rep; 2016 Sep; 36(3):1517-25. PubMed ID: 27459907
[TBL] [Abstract][Full Text] [Related]
30. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products.
Kunnumakkara AB; Guha S; Krishnan S; Diagaradjane P; Gelovani J; Aggarwal BB
Cancer Res; 2007 Apr; 67(8):3853-61. PubMed ID: 17440100
[TBL] [Abstract][Full Text] [Related]
31. Deoxyelephantopin induces apoptosis via oxidative stress and enhances gemcitabine sensitivity
Ji D; Zhong X; Huang P; Kang P; Leng K; Zheng W; Wang Z; Xu Y; Cui Y
Aging (Albany NY); 2020 Jun; 12(11):11116-11138. PubMed ID: 32526702
[TBL] [Abstract][Full Text] [Related]
32. Combined effect of dehydroxymethylepoxyquinomicin and gemcitabine in a mouse model of liver metastasis of pancreatic cancer.
Suzuki K; Aiura K; Matsuda S; Itano O; Takeuchi O; Umezawa K; Kitagawa Y
Clin Exp Metastasis; 2013 Apr; 30(4):381-92. PubMed ID: 23111540
[TBL] [Abstract][Full Text] [Related]
33. The oncogenic receptor ErbB2 modulates gemcitabine and irinotecan/SN-38 chemoresistance of human pancreatic cancer cells via hCNT1 transporter and multidrug-resistance associated protein MRP-2.
Skrypek N; Vasseur R; Vincent A; Duchêne B; Van Seuningen I; Jonckheere N
Oncotarget; 2015 May; 6(13):10853-67. PubMed ID: 25890497
[TBL] [Abstract][Full Text] [Related]
34. Modulation of pancreatic cancer chemoresistance by inhibition of TAK1.
Melisi D; Xia Q; Paradiso G; Ling J; Moccia T; Carbone C; Budillon A; Abbruzzese JL; Chiao PJ
J Natl Cancer Inst; 2011 Aug; 103(15):1190-204. PubMed ID: 21743023
[TBL] [Abstract][Full Text] [Related]
35. Antitumor activity of gemcitabine can be potentiated in pancreatic cancer through modulation of TLR4/NF-κB signaling by 6-shogaol.
Zhou L; Qi L; Jiang L; Zhou P; Ma J; Xu X; Li P
AAPS J; 2014 Mar; 16(2):246-57. PubMed ID: 24424498
[TBL] [Abstract][Full Text] [Related]
36. Inducing apoptosis and enhancing chemosensitivity to gemcitabine via RNA interference targeting Mcl-1 gene in pancreatic carcinoma cell.
Wei SH; Dong K; Lin F; Wang X; Li B; Shen JJ; Zhang Q; Wang R; Zhang HZ
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1055-64. PubMed ID: 18297287
[TBL] [Abstract][Full Text] [Related]
37. Enhanced antitumor efficacy by the combination of emodin and gemcitabine against human pancreatic cancer cells via downregulation of the expression of XIAP in vitro and in vivo.
Wang ZH; Chen H; Guo HC; Tong HF; Liu JX; Wei WT; Tan W; Ni ZL; Liu HB; Lin SZ
Int J Oncol; 2011 Nov; 39(5):1123-31. PubMed ID: 21743963
[TBL] [Abstract][Full Text] [Related]
38. Combination chemotherapy of nafamostat mesilate with gemcitabine for pancreatic cancer targeting NF-kappaB activation.
Uwagawa T; Chiao PJ; Gocho T; Hirohara S; Misawa T; Yanaga K
Anticancer Res; 2009 Aug; 29(8):3173-8. PubMed ID: 19661331
[TBL] [Abstract][Full Text] [Related]
39. Co-targeting of CXCR4 and hedgehog pathways disrupts tumor-stromal crosstalk and improves chemotherapeutic efficacy in pancreatic cancer.
Khan MA; Srivastava SK; Zubair H; Patel GK; Arora S; Khushman M; Carter JE; Gorman GS; Singh S; Singh AP
J Biol Chem; 2020 Jun; 295(25):8413-8424. PubMed ID: 32358063
[TBL] [Abstract][Full Text] [Related]
40. Double inhibition of NF-κB and XIAP via RNAi enhances the sensitivity of pancreatic cancer cells to gemcitabine.
Cao LP; Song JL; Yi XP; Li YX
Oncol Rep; 2013 Apr; 29(4):1659-65. PubMed ID: 23354694
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
